FDA Policy/General

FDA Flags Evolus Instagram Promotion for Jeuveau

FDA’s Office of Prescription Drug Promotion (OPDP) has cited Evolus over an Instagram promotion for wrinkle treatment Jeuveau (prabotulinumtoxinA-xvfs), saying the post exaggerated the drug's effectiveness and onset of action while minimizing serious risks. OPDP noted that it had raised similar concerns with Evolus in 2019 regarding promotional claims about Jeuveau’s onset of effect.

In a just-posted 9/28 untitled letter, OPDP said a patient testimonial and accompanying claims misleadingly suggest Jeuveau could make frown lines “gone,” provide “complete results” and produce meaningful results within two days. The agency said those representations were not supported by data used to establish the product’s effectiveness.

Jeuveau is approved for temporary improvement in the appearance of moderate-to-severe glabellar lines in adults. Its pivotal studies used a primary efficacy assessment at Day 30. FDA said the Day 2 results highlighted in the Instagram promotion came from an exploratory endpoint with important statistical limitations.

OPDP also took issue with a presentation that described Evolus as “blurring the lines” between products found in a consumer's beauty bag and treatments performed in a medical setting. FDA said the presentation misleadingly likened the prescription injectable to an everyday cosmetic product, despite the need for proper administration by a healthcare provider and the drug's serious risks.

Jeuveau carries a Boxed Warning for distant spread of toxin effects. FDA said risk information appeared only near the end of the Instagram reel and was not presented with prominence comparable to the product’s benefits.

FDA Unveils Transparency Roadmap — Plans More Disclosures

FDA has unveiled a new Transparency Roadmap that calls for expanded public disclosure of complete response letters, clinical study reports, inspection records and other regulatory information as part of a broader fiscal year 2027 transparency initiative. The roadmap builds on FDA’s 2025 initiative to publicly release complete response letters

FDA Grants Fast Track Status to Trethera’s Lung Cancer Drug

The FDA has granted fast track status to Trethera’s TRE-515 in combination with KRAS inhibitors for certain patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). The designation covers TRE-515 combined with KRAS inhibitors for patients with G12C mutation-positive NSCLC previously treated with an

FDA Urged to Clarify Rare Disease Approval Pathways

FDA’s new commissioner, once confirmed and sworn in, should provide greater clarity on regulatory pathways for rare disease therapies, especially the use of single-arm clinical trials, a rare disease advocate argued in a new Washington Examiner commentary. David Gusick said uncertainty over FDA’s expectations could delay development

Olympia Pharmaceuticals Hit With 483 Over Sterile Manufacturing

FDA has cited Olympia Pharmaceuticals for eight observations involving aseptic processing, environmental monitoring, component testing and other manufacturing controls following an inspection last month at the company's Orlando, FL, outsourcing facility. The Form 483 said Olympia’s aseptic processing areas had deficiencies in environmental and personnel monitoring. Investigators

Read more

FDA Unveils Transparency Roadmap — Plans More Disclosures

FDA Grants Fast Track Status to Trethera’s Lung Cancer Drug

FDA Urged to Clarify Rare Disease Approval Pathways

Olympia Pharmaceuticals Hit With 483 Over Sterile Manufacturing